Preeclampsia May Be Explained By Changes In Gene Expression During Pregnancy
Virginia Commonwealth University School of Medicine researchers have discovered that changes in the gene expression of a key enzyme may contribute to high blood pressure and increase susceptibility to forming blood clots in pregnant women with preeclampsia.
These findings could provide clues to the best treatment approaches for high blood pressure and the formation of blood clots that can block blood flow to a pregnant woman's internal organs and lead to organ failure.
Researchers have been working to determine the root cause of preeclampsia on the molecular level and have now identified that epigenetic mechanisms may be at play. Epigenetics refers to changes in gene expression that are mediated through mechanisms other than changes in the DNA sequence.
In a study published online in Hypertension, a journal of the American Heart Association, the VCU team reported that thromboxane synthase - an important inflammatory enzyme - is increased in the blood vessels of expectant mothers with preeclampsia. The thromboxane synthase gene codes for this enzyme, which is involved in several processes including cardiovascular disease and stroke. This enzyme results in the synthesis of thromboxane, which increases blood pressure and causes blood clots.
"The present work is unique because it opens up a new concept as to the cause and subsequent consequences of preeclampsia relating to epigenetics," said corresponding author Scott W. Walsh, Ph.D., professor in the VCU Department of Obstetrics and Gynecology. "It is the first study to show that epigenetic alterations in the blood vessels of the mother are related to preeclampsia."
According to Walsh, one of the main epigenetic mechanisms is methylation of the DNA, which controls the expression of genes. The increase of this enzyme in the blood vessels is related to reduced DNA methylation and the infiltration of neutrophils into the blood vessels. Neutrophils are white blood cells that normally help fight infection.
In the future, Walsh said some potential treatments for preeclampsia may include inhibition of thromboxane synthase, blockade of thromboxane receptors or dietary supplementation with folate. He said that folate supplementation could increase methylation donors to protect against adverse changes in DNA methylation that affect expression of the thromboxane synthase enzyme.
This study builds on previously published work by the VCU team that appeared in the November 2011 issue of Hypertension and in the January 2011 issue of the American Journal of Pathology and demonstrated a significant role for neutrophils as causative agents of high blood pressure in preeclampsia.
Added: 04 мая 2012
Added: 04 мая 2012
Last relative articles:
- Understanding How Arteries Control Blood Pressure
- Treatment With RAAS Inhibitors Found To Save Lives In Hypertension Study
- People With High Blood Pressure Can Reduce Their Mortality Risk By Exercising
- Being Obese Or Underweight Can Cause Risks In Pregnancy
- Maxonidine, A Second-Generation Drug Used For Hypertension Aids Heart Function Independent Of Blood Pressure
- Pulmonary Arterial Hypertension - Phase III SERAPHIN Outcome Study Meets Primary Endpoint
- Increasing Blood Pressure Screening May Reduce Incidence Of CVD Events And Death By Up To 3 Percent
- Cardiovascular Disease Deaths Could Be Reduced By Tax On Salt
- Fighting Harmful Free Radicals Tied To Aging And Cancer With Avocado Oil: The 'Olive Oil Of The Americas'?
- More Research Needed Into The Fetal Effects Of Some Drugs During Pregnancy
- Treatment With Nitric Oxide Led To Sustained Normalization Of Blood Pressure In An ASA Mouse Model
- A Serving A Day Of Dark Chocolate Might Keep The Doctor Away
- Old Age Sees Decrease In Cardiovascular Disease Risk Of High Normal Blood Pressure
- High Doses Of Vitamin C May Lower Blood Pressure
- Blood Pressure Medicine Nifedipine Increases Risk For Heart Attacks And Death